Hannah Wen | Breast Cancer | Best Researcher Award

Published on by Cell Biologist

Dr. Hannah Wen | Breast Cancer | Best Researcher Award

Dr. Hannah Wen, MEMORIAL SLOAN KETTERING CANCER CENTER, United States

Dr. Hannah Y. Wen, M.D., Ph.D., is a distinguished breast cancer pathologist and cancer researcher at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. With dual training in medicine and cancer biology, Dr. Wen’s career reflects a deep commitment to advancing the field of translational oncology. Her research focuses on triple-negative breast cancer (TNBC), rare breast tumor subtypes, and predictive/prognostic biomarkers. Dr. Wen is a prolific academic contributor with publications in high-impact journals such as Nature Communications and Cancer Research. She integrates molecular biology with diagnostic pathology to improve cancer stratification and therapy decisions. In addition to her investigative work, she contributes as a principal investigator on multiple IRB-approved studies at MSKCC. Recognized with early academic accolades and continuously advancing the frontiers of cancer pathology, Dr. Wen exemplifies the blend of scientific rigor and clinical relevance. She is a strong candidate for any prestigious research award in pathology and oncology.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Academic Training
    Dr. Wen holds an M.D. from Peking University Health Science Center, one of China’s top medical schools, and a Ph.D. in Cancer Biology from MD Anderson Cancer Center, a global leader in cancer research.

  2. Robust Postdoctoral and Clinical Research Experience
    Her postdoctoral work at Genentech Inc. and ongoing clinical-scientific role at Memorial Sloan Kettering Cancer Center (MSKCC) place her at the intersection of innovative molecular research and high-impact clinical diagnostics.

  3. High-Impact Publications
    She has authored landmark papers in journals like Cancer Research, Nature Cell Biology, PNAS, Modern Pathology, and Nature Communications, covering diverse areas such as:

    • Triple-negative breast cancer

    • Genetic markers (e.g., BRCA1, p202)

    • Molecular subtyping of rare breast tumors

    • Pathologic stratification of early-stage breast cancer

  4. Active Investigator and IRB Leadership
    Dr. Wen is Principal Investigator for multiple MSK IRB protocols involving rare breast cancer subtypes and molecular markers. This shows strong leadership in translational research.

  5. Recognition and Consistency
    From receiving Top 10 Student Awards in Beijing to leading diagnostic-pathologic breakthroughs in 2025, her excellence spans over three decades.

Areas for Improvement:

  1. Visibility of Awards in the U.S. Academic System
    While her early academic awards are impressive, more documented recent honors, society memberships, or fellowships could further enhance her candidacy.

  2. Mentorship and Teaching Roles
    While likely involved, specific mention of mentorship, educational leadership, or curriculum development would strengthen her profile in academic impact.

  3. Interdisciplinary Collaborations
    Explicit examples of cross-disciplinary collaborations (e.g., computational oncology, AI in pathology) would underscore her innovation potential in modern biomedical research.

Education:

Dr. Hannah Y. Wen obtained her M.D. from Peking University Health Science Center, Beijing, China (1988–1993), where she was consistently recognized as an outstanding student. She pursued her Ph.D. in Cancer Biology at the University of Texas Health Science Center/MD Anderson Cancer Center in Houston, TX (1997–2001), focusing on molecular oncology. During her Ph.D., she contributed significantly to understanding interferon-inducible proteins in cancer suppression. Her educational journey reflects deep interdisciplinary training, combining clinical medicine with cutting-edge research. This robust academic background has laid the foundation for her success in translational cancer research and diagnostic pathology. Dr. Wen’s training continues with postdoctoral work at Genentech Inc. in Experimental Pathology, which further honed her molecular diagnostic skills. Her global academic trajectory—from China to elite U.S. institutions—has shaped her into a well-rounded researcher capable of addressing complex challenges in breast cancer diagnosis and treatment.

Experience:

Dr. Wen brings over two decades of research and clinical experience in cancer biology and diagnostic pathology. After completing her Ph.D. at MD Anderson Cancer Center, she conducted postdoctoral research in Experimental Pathology at Genentech, Inc., South San Francisco (2002–2003). Since then, she has held a faculty position at the Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center. At MSKCC, Dr. Wen has served as Principal Investigator on multiple IRB-approved protocols investigating rare breast cancer subtypes and genetic alterations. Her daily work bridges histopathology and genomics to advance precision medicine in breast cancer. Beyond research, she mentors fellows and contributes to academic committees, reinforcing her role as a leader in her field. Her hands-on experience with triple-negative breast cancer, breast tumor markers, and breast pathology variants gives her a rare clinical-research dual expertise, making her a vital figure in contemporary breast cancer diagnostics.

Awards and Honors:

Dr. Hannah Y. Wen has received numerous recognitions throughout her academic journey. Early in her career, she was honored with the Outstanding Student Award by Peking University Health Science Center (1988–1992), a distinction granted to top-tier medical students. She was also named among Beijing’s Top 10 Outstanding Students in 1992, recognizing her academic and leadership excellence. While formal awards during her U.S. career are not extensively documented in the data provided, Dr. Wen’s growing impact in high-impact journals and role as a Principal Investigator at MSKCC are implicit accolades in the competitive world of academic medicine. Her contributions to translational breast cancer research, including studies on BRCA1 inactivation and tumor progression markers, underscore her continuous excellence. Given her record of impactful research and professional standing at one of the world’s leading cancer centers, she remains a strong contender for recognition such as the Best Researcher Award.

Research Focus:

Dr. Wen’s research centers on triple-negative breast cancer (TNBC), a challenging and aggressive subtype of breast cancer with limited therapeutic targets. She also investigates rare and under-recognized breast tumor subtypes such as microglandular adenosis, acinic cell carcinoma, and tall cell carcinoma with reversed polarity. Her work involves the identification of predictive and prognostic markers, employing techniques such as targeted gene sequencing, BRCA1 methylation analysis, and molecular stratification models. As Principal Investigator, she leads studies under MSK IRB Protocols #16-411 and #16-596, exploring the genomic and epigenetic landscape of TNBC. Her research stands out for its clinical translation, directly impacting patient diagnosis and treatment planning. Recent contributions to Nature Communications and Modern Pathology show her innovative use of multimodal histopathological models and molecular profiling. Dr. Wen’s research reflects a powerful blend of diagnostic pathology, molecular genetics, and precision oncology—positioning her as a leader in breast cancer research.

Publications Top Notes:

  1.  The Role of Platelet Activating Factor in Reproduction – Progress of Anatomical Sciences (1996)

  2.  Transforming Growth Factor-α and Its Receptor in Reproduction – Medical Sciences (1997)

  3.  TGF-α Expression in Mouse Embryos and Uterus – J. Beijing Medical Univ. (1997)

  4.  p202 Slows Prostate Cancer Cell Growth – Oncogene (1999)

  5.  p202 Enhances TNF-α-Induced Apoptosis in Breast Cancer – Cancer Research (2000)

  6.  β-catenin as a Prognostic Marker in Breast Cancer – PNAS USA (2000)

  7.  HER-2/neu Drives Androgen-Independent Prostate Cancer – Cancer Research (2000)

  8.  EGFR’s Nuclear Role as a Transcription Factor – Nature Cell Biology (2001)

  9.  p202 Mediates Anti-Tumor Activity in Pancreatic Cancer – Cancer Research (2001)

  10.  Systemic Tumor Suppression via Bik Gene – Cancer Research (2002)

Conclusion:

Dr. Hannah Y. Wen is a highly qualified and deserving nominee for the Best Researcher Award. Her outstanding academic background, consistent and impactful research output, and leadership in breast cancer pathology make her a top-tier researcher in the field of translational oncology. She excels in integrating molecular biology with diagnostic pathology to improve cancer detection, stratification, and treatment.

With minor enhancements in visibility and cross-disciplinary leadership, Dr. Wen is not only suitable but a model candidate for this award. Her work is advancing breast cancer care at both the bench and bedside—fulfilling the core mission of research excellence.

Jin-Feng Hu | Molecular Mechanisms Signaling | Distinguished Scientist Award

Published on by Cell Biologist

Prof. Jin-Feng Hu | Molecular Mechanisms Signaling | Distinguished Scientist Award

Prof. Jin-Feng Hu , School of Pharmaceutical Sciences, Taizhou University, Zhejiang 318000, PR China ,China

Dr. Jin-Feng Hu is a globally recognized natural products chemist and currently serves as the Dean and Principal Investigator at the School of Pharmaceutical Sciences, Taizhou University, Zhejiang, China. With over three decades of academic and research experience, Dr. Hu has dedicated his career to discovering and developing bioactive natural products, particularly from rare and endangered plant species endemic to China. His contributions span innovative phytochemistry, drug discovery, and chemical biology. He has previously held prestigious academic positions at Fudan University and East China Normal University. Dr. Hu’s collaborations span continents, including Germany and the USA, contributing to an impressive international research profile. His work is widely published in high-impact journals and highly cited, underscoring the scientific relevance and translational potential of his discoveries.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Prolific Contributions to Natural Products Chemistry
    Dr. Hu has made significant breakthroughs in phytochemical research, particularly focusing on rare and endangered Chinese plants, contributing both to drug discovery and biodiversity conservation.

  2. Global Research Experience
    His training and postdoctoral fellowships in leading institutions across China, Germany, and the USA (including the Hans-Knoell-Institute and the Scripps Research Institute) add to his international reputation and collaborative strength.

  3. Academic Leadership & Institutional Impact
    As a former department chair at Fudan University and current Dean at Taizhou University, Dr. Hu has not only led cutting-edge research but also shaped the academic direction of major pharmaceutical programs.

  4. High-Impact Publications
    Multiple first or last-author papers published in leading journals such as Phytochemistry, Organic Chemistry Frontiers, Bioorganic Chemistry, and Molecules—with a focus on pharmacologically relevant compounds.

  5. Innovative Research Themes
    Focused on drug resistance, inflammation, and metabolic diseases, using unique molecules like bis-diterpene heterodimers and sesquiterpenes, often with novel skeletons—this shows originality and translational potential.

⚙️ Areas for Improvement:

  1. Wider Public Recognition
    While he is highly respected in academic and pharmaceutical chemistry circles, broader science communication or participation in international awards/societies could boost global visibility.

  2. Commercialization & Patents
    Encouraging the translation of discoveries into patents or clinical trials would further highlight the real-world impact of his research.

  3. International Grant Funding
    Expansion into multinational funding sources (e.g., NIH, EU Horizon) would solidify global research integration and amplify the scale of his discoveries.

🎓 Education:

Dr. Hu earned his B.S., M.S., and Ph.D. degrees in Organic Chemistry from Lanzhou University (1986–1996). He pursued advanced training and postdoctoral research in Natural Products Chemistry at the Institute of Materia Medica, Chinese Academy of Medical Sciences, followed by a prestigious BMBF Fellowship at the Hans-Knoell-Institute (HKI) in Germany. Dr. Hu then continued his postdoctoral work in the United States—first at the University of Mississippi focusing on natural products chemistry and later at the Genomics Institute of the Novartis Research Foundation/The Scripps Research Institute, in the laboratory of renowned chemist Prof. Peter G. Schultz. His academic journey across leading institutions in China, Germany, and the US provided a robust foundation in interdisciplinary sciences and global perspectives in medicinal chemistry.

🧪 Experience:

Dr. Hu currently serves as Full Professor, Principal Investigator, and Dean of the School of Pharmaceutical Sciences at Taizhou University (2021–present). Before this, he was Chair of the Department of Natural Products Chemistry at Fudan University (2011–2021), and prior to that, Deputy Director of the MOE Key Laboratory of Brain Functional Genomics at East China Normal University (2006–2011). In each position, he has led cutting-edge research in natural products, coordinated multi-institutional collaborations, mentored numerous young scientists, and managed institutional development. His lab integrates phytochemistry, structural biology, and drug discovery platforms, focusing particularly on therapeutic leads for antimicrobial resistance, cancer, and metabolic diseases. With a career that reflects both academic excellence and applied innovation, Dr. Hu has significantly contributed to China’s leadership in pharmaceutical science.

🏆 Awards and Honors:

Dr. Hu has received multiple national and international honors, including fellowships, research grants, and awards recognizing his excellence in natural products chemistry. He was a BMBF Research Fellow in Germany, a Postdoctoral Fellow at the Novartis Genomics Institute and The Scripps Research Institute in the US, and has been a recipient of several Chinese National Natural Science Foundation awards. His leadership roles at prestigious institutions like Fudan University and East China Normal University reflect the esteem he holds within the academic community. Moreover, his publications are widely cited, and his research frequently garners attention for its innovation and societal relevance, especially in the context of preserving biodiversity and discovering drugs from endangered species. These achievements make him an outstanding candidate for a Distinguished Scientist Award.

🔬 Research Focus:

Dr. Hu’s research is centered on the discovery and development of novel bioactive compounds from rare and endangered plants endemic to China. His work emphasizes the interface of phytochemistry, chemical biology, and drug discovery, employing integrative analytical techniques like NMR, LC-MS, and bioassays. A major focus is the identification of natural inhibitors of key metabolic enzymes such as ATP-citrate lyase and ACC1, with applications in metabolic disorders and cancer. His studies also target drug-resistant bacterial infections, inflammation, and neurodegenerative diseases. By studying plants that are ecologically valuable yet scientifically underexplored, Dr. Hu not only contributes to new therapeutic leads but also aids in conservation biology and chemotaxonomy. His approach of combining traditional Chinese medicinal knowledge with modern molecular science marks him as a trailblazer in natural products-based drug discovery.

📚 Publication Top Notes:

  1. 🌲 Spiroamentotaxols A−D from Amentotaxus yunnanensis and their bioactivities – Organic Chemistry Frontiers (2025)

  2. 🍃 Fortunefuroic acids from Keteleeria fortunei via integrated dereplication approach – Phytochemistry (2025)

  3. 🌿 Benzofurans from Parrotia subaequalis with antimicrobial activity – Phytochemistry (2025)

  4. 🌸 Bis-iridoid glycosides and triterpenoids from Kolkwitzia amabilis targeting ACC1 and ACL – Molecules (2024)

  5. 🍂 Platanosides from Platanus acerifolia against drug-resistant infections – Bioorganic Chemistry (2024)

  6. 🌼 Natural products from Heptacodium miconioides and their classification significance – Phytochemistry (2024)

  7. 🌲 Tsugaforrestiacids A–O from Tsuga forrestii with ATP-citrate lyase inhibition – Phytochemistry (2024)

  8. 🌲 Terpenoids from Pseudotsuga forrestii as DRAK2 inhibitors – Journal of Molecular Structure (2024)

  9. 🍁 Anti-inflammatory flavonoids from Platanus acerifolia leaves – Phytochemistry Letters (2024)

  10. 🌴 Fortunefuroic acid J from Keteleeria hainanensis with dual inhibitory effects – Chemistry & Biodiversity (2024)

🔚 Conclusion:

Dr. Jin-Feng Hu is an exceptionally qualified candidate for the Distinguished Scientist Award. His trailblazing research in natural products chemistry, strategic leadership in academic institutions, and commitment to preserving biodiversity through medicinal innovation position him as a thought leader in his field. His work not only expands the scientific frontier of phytochemical drug discovery but also addresses urgent global health concerns such as antibiotic resistance and metabolic disease. Recognizing Dr. Hu with this award would honor a career devoted to science, mentorship, and societal benefit, while also empowering his continued excellence in the years to come.